Determining the detailed mechanisms by which variants in the human genome or genes associated with human genetic variants operate to contribute to disease or health/wellness.
News | Variants to Function & Mechanism
Association of Soluble ST2 With Functional Outcome, Perihematomal Edema, and Immune Response After Intraparenchymal Hemorrhage
This manuscript builds on the Kimberly Lab’s work that highlights the role of the interleukin-33/ST2 pathway and its link to post-stroke inflammation and brain edema. The lab had previously shown that this inflammatory signaling cascade is associated with brain edema and activation of innate immunity after ischemic stroke and subarachnoid hemorrhage. This paper extends previous work to show a similarly damaging activation after intracerebral hemorrhage. Collectively, this work highlights that modulation of the IL-33/ST2 pathway is a candidate target to reduce the severity of edema and inflammation after all major forms of acute brain injury.
Read more in Neurology
Uridine and RNA as energy
To identify genes and pathways that cells can use to survive when glucose — an important source of energy and carbon — is limited, Vamsi Mootha, and colleagues performed genome-wide genetic screens and a PRISM growth assay. They found that cells ranging from healthy immune cells to cancer cells can use uridine, a component of RNA, as an energy source when glucose is unavailable. Targeting the biochemical pathway that cells use to break down uridine-derived sugar could help treat cancers and metabolic disorders and tune the immune response.
Read more in Nature Metabolism, a Broad news story, and a tweetorial by Alexis Jourdain.
Clonal haematopoiesis and risk of chronic liver disease.
Through advances in population-based genomic sequencing an analysis, the Natarajan lab and others showed that ‘clonal hematopoiesis of indeterminate potential’ (CHIP) is a surprisingly common feature as we age. They also showed that CHIP plays a role in coronary artery disease, the leading contributor to death in the US and now globally. As inflammation appeared to be a principal driver, the Natarajan lab has since then attempted to understand whether CHIP plays a role in other conditions where inflammation has been invoked as a key driver. This study focused on chronic liver disease because, which has become increasingly common with the rising prevalence of obesity and metabolic syndrome. However, therapeutic options for chronic liver disease have remained limited for decades except for hepatitis C. Fatty liver disease is increasingly recognized but the reasons by inflammation and downstream liver disease occur remain limited. They therefore hypothesized that CHIP could play a role. It was found that CHIP offered to confer a relatively large risk for chronic liver disease, sometimes larger than currently recognized risk factors. And causal inference approaches, such as Mendelian randomization, supported a potential causal relationship. Liver MRIs and liver biopsies were consistent with greater steatohepatitis and not greater steatosis. Murine models similarly showed greater steatohepatitis without greater steatosis, and also greater fibrosis when followed for longer periods of time. Genetic deficiency of the NLRP3 inflammasome appeared to ameliorate this phenotype in the mice. This inflammatory pathway has also been invoked in CHIP-associated coronary artery disease. The relationship between CHIP and liver disease was previously unknown. These observations highlight a new potential precision medicine paradigm for chronic liver disease prevention. The findings support the scientific premise that, particularly for TET2 CHIP, inhibition of the NLRP3 inflammasome may reduce the risk of chronic liver disease.
Read more in Nature.
Read more in Nature.
Nucleosides Associated With Incident Ischemic Stroke in the REGARDS and JHS Cohorts
This manuscript is the first to show a link between specific nucleoside metabolites and the risk of future stroke, independent of traditional stroke risk factors. In this study, CGM Investigator Taylor Kimberly and colleagues also sought to determine whether these candidates were a reflection of genes or environment through GWA studies. Their findings suggest that the top metabolites were related to environmental or behavioral patterns, ultimately leading our group to focus on potential links between diet, the gut microbiome, and stroke risk.
Read more in Neurology.
Brain-specific deletion of GIT1 impairs cognition and alters phosphorylation of synaptic protein networks implicated in schizophrenia susceptibility
The molecular and cellular basis of cognitive deficits in schizophrenia remains poorly understood. Recent progress in elucidating the genetic architecture of schizophrenia has highlighted the association of multiple loci and rare variants that may impact susceptibility. A critical next step is to delineate specifically how such genetic variation impacts synaptic plasticity and to determine if and how the encoded proteins interact biochemically. Towards this goal, CGM Investigator Steve Haggarty and colleagues studied the roles of GPCR-kinase interacting protein 1 (GIT1), a synaptic scaffolding protein with damaging coding variants found in schizophrenia patients, as well as copy number variants found in patients with neurodevelopmental disorders. Profiling GIT1 knockout mice revealed memory deficits and reduced cortical dendritic spine density. Using global quantitative phospho-proteomics, we revealed that GIT1 deletion perturbs specific networks of synaptic proteins, suggesting that GIT1 regulates the phosphorylation of critical regulators of neuroplasticity.
Read more in Molecular Psychiatry
December 8, 2022
Publication
CGM Primary Investigator
Distinct effects of interleukin-6 and interferon-γ on differentiating human cortical neurons
The Karmacharya lab interrogated neurodevelopmental effects of exposure to interleukin-6 (IL-6) and interferon-γ (IFN-γ) in differentiating human cortical neurons. Transcriptomic analyses showed IL-6 exposure affected genes regulating extracellular matrix, actin cytoskeleton and TGF-β signaling while IFN-γ exposure impacted genes regulating antigen processing, major histocompatibility complex and endoplasmic reticulum biology. IL-6 altered mitochondrial respiration in the differentiated neurons while IFN-γ induced reduction in dendritic spine density. Pretreatment with folic acid ameliorated IL-6 effects on mitochondrial respiration and IFN-γ effects on dendritic spine density. These findings suggest cellular processes that mediate maternal immune activation in developing brains and how folic acid mitigates such risk.
Read more in Brain Behavior and Immunity
December 7, 2022
Publication
CGM Primary Investigator
Rakesh Karmacharya
Faculty | Variants to Function & Mechanism
Christopher D. Anderson, MD, MMSc
Associate Neurologist, Massachusetts General Hospital
Associate Professor of Neurology, Harvard Medical School
Dr. Anderson is a Neurocritical Care physician with research expertise in the medical genetics of complex diseases, specifically ischemic and hemorrhagic stroke. His career research goal is to use computational, genetic, and epidemiologic tools to derive new information about the mechanisms underlying cerebrovascular disease, and to use this information to drive improvement in stroke care through the identification of novel treatment targets and implementation of precision strategies for primary and secondary prevention.
Christopher D. Anderson, MD, MMSc
Associate Professor of Neurology, Harvard Medical School
Raghu R. Chivukula, MD, PhD
Assistant Physician, Massachusetts General Hospital
Assistant Professor of Medicine, Harvard Medical School
We are currently most interested in identifying and mechanistically dissecting genetic disorders affecting the biogenesis, trafficking, and function of subcellular compartments (organelles) in specialized cells of the lungs. We aim to apply an understanding of such rare diseases both to uncover new cell biology and to develop novel therapeutic approaches which target fundamental, initiating steps in pulmonary diseases.
Raghu R. Chivukula, MD, PhD
Assistant Professor of Medicine, Harvard Medical School
Melina Claussnitzer, PhD
Investigator, Massachusetts General Hospital
Associate Professor of Medicine, Harvard Medical School
The Claussnitzer lab pioneers Variant-to-Function (V2F) strategies for metabolic diseases.
Melina Claussnitzer, PhD
Associate Professor of Medicine, Harvard Medical School
Susan L. Cotman, PhD
Assistant in Neuroscience, Massachusetts General Hospital
Assistant Professor of Neurology, Harvard Medical School
The Cotman laboratory’s research is focused on understanding the role of the endosomal-lysosomal system in human disease, with a particular emphasis on NCL (Batten disease), the most common cause of neurodegeneration in childhood that also more rarely affects adults.
Susan L. Cotman, PhD
Assistant Professor of Neurology, Harvard Medical School
Mark J. Daly, PhD
Chief, ATGU, Massachusetts General Hospital
Associate Professor of Medicine, Harvard Medical School
The Daly Lab focuses on computational approaches to understanding the genetics of human disease using integrative genomics approaches. The lab has extensive experience in linkage and association analysis, with a focus on developing statistical methods for the design and interpretation of association studies, and applying these approaches specifically to major common disease areas such as neuropsychiatric disease, inflammatory bowel and autoimmune diseases, and diabetes.
Mark J. Daly, PhD
Associate Professor of Medicine, Harvard Medical School
Erin C. Dunn, MPH, ScD
Associate Investigator, Massachusetts General Hospital
Associate Professor, Harvard Medical School
Our research seeks to understand the drivers of both mental illness and mental wellbeing across the lifespan. Much of our work has focused on the social and biological underpinnings of depression and anxiety among women, children, adolescents, and other vulnerable populations, including racial/ethnic minorities and people of low socioeconomic status.
We study a range of biological factors and processes contributing to mental health—including the role of genetic variation and epigenetic mechanisms—as well as biological markers of future risk, such as markers captured in children’s primary (or baby) teeth.
We study multiple social factors, including the role of early life environmental exposures and stressors such as childhood adversity, on mental health.
Erin C. Dunn, MPH, ScD
Associate Professor of Psychiatry, Harvard Medical School
Florian Eichler, MD
Director, Center for Rare Neurological Diseases, Massachusetts General Hospital
Professor of Neurology, Harvard Medical School
Katherine B. Sims Chair in Neurogenetics
Our laboratory at MGH explores the relationship of mutant genes to specific biochemical defects and their contribution to neurodegeneration. To develop novel treatments, our laboratory assesses the consequences of disease causing genes.
Florian Eichler, MD
Professor of Neurology, Harvard Medical School
Hilary K. Finucane, PhD
Assistant in Investigation, Massachusetts General Hospital
Assistant Professor of Medicine, Harvard Medical School
Our group develops and applies new statistical and computational methods for analyzing biological data. Our main focus is on integrating genetic data about disease with molecular data about cell types and biological processes to learn about the causes of disease. We are based at the Broad Institute and Massachusetts General Hospital.
Hilary K. Finucane, PhD
Assistant Professor of Medicine, Harvard Medical School
Jose C. Florez, MD, PhD
Chief, Endocrine Division and Diabetes Unit, Massachusetts General Hospital
Professor of Medicine, Harvard Medical School
The Florez lab aims to unravel the genetic basis of type 2 diabetes, related metabolic traits and its vascular complications, and provide the rationale for effective, precision-tailored therapies. The overarching goal is to bring the clinical treatment of diabetes and its complications into the new paradigm of molecular medicine, using genomic, metabolomic, experimental, physiological and pharmacogenetic approaches.
Jose C. Florez, MD, PhD
Professor of Medicine, Harvard Medical School
Yulia Grishchuk, PhD
Assistant Investigator, Massachusetts General Hospital
Assistant Professor of Neurology, Harvard Medical School
Our research is focused on pre-clinical studies and biomarker discovery for rare pediatric neurologic diseases with high unmet need to enable further development of therapies. Our therapeutic strategies have been focused on use of adeno-associated viral vectors for optimized transduction and transgene delivery to central nervous system, including brain, retina, and optic nerve.
Yulia Grishchuk, PhD
Assistant Professor of Neurology, Harvard Medical School
James F. Gusella, PhD
Research Staff, Massachusetts General Hospital
Bullard Professor of Neurogenetics in the Department of Genetics, Harvard Medical School
Dr. Gusella’s laboratory is currently pursuing collaborative studies at all stages of the genetic research cycle aimed at discovering genes that cause, predispose to or modify neurological and behavioral disorders or caused abnormal development in subjects with balanced chromosomal aberrations and developmental phenotypes, delineating mechanisms of pathogenesis and modifiers in Huntington’s disease, the neurofibromatosis, and autism and exploring the potential for mechanism-based treatments.
James F. Gusella, PhD
Bullard Professor of Neurogenetics in the Department of Genetics, Harvard...
Stephen J. Haggarty, PhD
Associate Neuroscientist, Massachusetts General Hospital
Associate Professor of Neurology, Harvard Medical School
The Haggarty Laboratory seeks to elucidate and modulate the molecular mechanisms underlying neuroplasticity, the brain’s ability to change and reorganize its structure, function, and connections in response to various experiences and learning, for the prevention and treatment of psychiatric and neurological disorders.
Stephen J. Haggarty, PhD
Associate Professor of Neurology, Harvard Medical School
Hailiang Huang, PhD
Assistant Investigator, Massachusetts General Hospital
Assistant Professor of Medicine, Harvard Medical School
The Huang Lab develops and applies cutting-edge statistical genetics and computational techniques to understand the genetic architecture of human complex disorders, especially autoimmune and psychiatric disorders. We are especially interested in novel methods to leverage cross-ancestry genomics data for insights into the disease pathogenesis.
Hailiang Huang, PhD
Assistant Professor of Medicine, Harvard Medical School
Konrad J. Karczewski, PhD
Assistant in Investigation, Massachusetts General Hospital
Instructor in Medicine, Harvard Medical School
Our research is focused on interpreting putative disease variants in common and rare diseases to improve our understanding of human disease and the regulation of the human genome. We do so by assembling and analyzing massive public datasets of genetic variation and functional genomics, building scalable tools and methods to keep pace with the exponential growth of these data types.
Konrad J. Karczewski, PhD
Instructor in Medicine, Harvard Medical School
Rakesh Karmacharya, MD, PhD
Physician Investigator, Massachusetts General Hospital
Associate Professor, Harvard Medical School
Our lab uses experimental approaches at the intersection of chemical biology, genetics and stem cell biology to investigate cellular pathways relevant to schizophrenia, bipolar disorder, autism and related neuropsychiatric disorders. We utilize complementary approaches in specific cellular subtypes and in three-dimensional cerebral organoids generated from human iPSCs. We employ a range of methods including high-content imaging to investigate synaptic biology, multi-electrode arrays to examine neuronal function along with transcriptomic, proteomic and metabolomic experiments. We seek to develop new small molecules that can modulate disease-related processes in patient-derived neurons and develop new therapeutic approaches for targeting cognitive deficits in psychiatric disorders.
Rakesh Karmacharya, MD, PhD
Associate Professor of Psychiatry, Harvard Medical School
W. Taylor Kimberly, MD, PhD
Chief, Division of Neurocritical Care, Massachusetts General Hospital
Associate Professor of Neurology, Harvard Medical School
The Kimberly Lab is committed to reducing the devastating effects of acute brain injury by focusing on translational studies that bridge basic science and clinical research. We believe that therapeutic discovery is not a linear path from fundamental mechanism to new drug, but instead a cycle that requires bi-directional and multidisciplinary integration of basic and patient-oriented research. A presence at each stage of discovery—both directly and through strategic collaboration—is central to our mission to advancing new treatments. Consequently, our laboratory is highly multidisciplinary and collaborative, and our work could not be accomplished without our collaborative partners.
W. Taylor Kimberly, MD, PhD
Associate Professor of Neurology, Harvard Medical School
Ben P. Kleinstiver, PhD
Investigator; Kayden-Lambert MGH Research Scholar 2023-2028, Massachusetts General Hospital
Assistant Professor, Harvard Medical School
The Kleinstiver lab develops genome editing technologies for research applications and for the treatment of human diseases. We develop new approaches and methods to engineer genome editing enzymes, to optimize the properties of CRISPR tools, and to add new functionalities to the editor toolbox, all with the ambition of enabling new treatments for disease.
Ben P. Kleinstiver, PhD
Assistant Professor of Pathology, Harvard Medical School
Jong-Min Lee, PhD
Associate Investigator, Massachusetts General Hospital
Associate Professor, Harvard Medical School
My lab is focused on studying underlying mechanisms and genetic modifiers of neurodegenerative diseases including Huntington’s disease to develop rational therapeutic strategies. For this, we are taking integrated approaches focusing on observations in humans. Major focus areas that are critical to understand pathogenesis and to develop therapeutic strategies include: 1) investigation of molecular mechanisms of tissue specificity, 2) identification of early molecular events, 3) discovery and functional follow-up of genetic modifiers, 4) investigation of genome instability, and 5) developing allele-specific genome editing strategies to address disease-causing mutations.
Jong-Min Lee, PhD
Associate Professor of Neurology, Harvard Medical School
Phil H. Lee, PhD
Associate Professor, Massachusetts General Hospital
Associate Professor, Harvard Medical School
We use computational and statistical approaches to understand the genetic bases of complex neuropsychiatric traits and mental disorders. Multivariate pathway analysis forms the backbone of our research on identifying disease risk genes and mechanisms. We also apply multi-modal data analysis integrating genomic and neuroimaging data.
Phil H. Lee, PhD
Associate Professor of Psychiatry, Harvard Medical School
Marcy E. MacDonald, PhD
Research (Non-Clinical) Staff, Massachusetts General Hospital
Professor of Neurology, Harvard Medical School
Our research, evolving from the discovery of the genetic causes of inherited brain disorders (hereditary spastic paraparesis, neurofibromatosis, neuronal ceroid lipofuscinosis, Huntington’s disease), is now largely focused on the DNA variants that modify the effects of the unstable expanded CAG repeat that causes Huntington’s disease. We do molecular genetic studies with disease and population cohorts and genetically precise model systems. Our goal is to enable timely intervention, diagnosis and disease-management.
Marcy E. MacDonald, PhD
Professor of Neurology, Harvard Medical School
Vamsi K. Mootha, MD
Principal Investigator, Massachusetts General Hospital
Professor of Systems Biology, Harvard Medical School
The long-term goals of the Mootha Laboratory are to combine the new tools of genomics and systems biology with classic biochemistry to investigate mitochondrial bioenergetics, evolution, and disease.
Vamsi K. Mootha, MD
Professor of Systems Biology, Harvard Medical School
Patricia L. Musolino, MD, PhD
Physician-Scientist, Massachusetts General Hospital
Associate Professor of Neurology, Harvard Medical School
The Musolino Laboratory at the Center for Genomic Medicine at Massachusetts General Hospital and Harvard Medical School is a translational neuroscience laboratory focusing on developing gene targeted therapies for inherited inborn errors of metabolism and cerebrovascular disorders that lead to stroke and leukodystrophy.
Patricia L. Musolino, MD, PhD
Associate Professor of Neurology, Harvard Medical School
Benjamin M. Neale, PhD
Associate Investigator, Massachusetts General Hospital
Associate Professor of Medicine, Harvard Medical School
The Neale lab focuses on uncovering the genetic risk factors of common disease, in particular through international collaboration to diversify the global representation of study participants, as well as the research community involved in such efforts. We develop statistical methods and computational tools to enable efficient and scalable analysis of the growing datasets available in genetic sequencing studies.
Benjamin M. Neale, PhD
Associate Professor of Medicine, Harvard Medical School
Aarno Palotie
Lecturer, Harvard Medical School
Group Leader, Massachusetts General Hospital
Understanding disease genetics using the Finnish founder population
Aarno Palotie
Lecturer, Harvard Medical School Group Leader, Massachusetts General Hospital Understanding...
Roy H. Perlis, MD
Associate Chief for Research, Department of Psychiatry, Massachusetts General Hospital
Professor of Psychiatry, Harvard Medical School
Our lab focuses on developing clinical and genomic predictors of treatment response, and on developing novel therapeutics based on cellular models of brain disease. We use cellular modeling, transcriptomics, clinical phenotyping, and small molecule screening to study psychiatric disorders including schizophrenia, bipolar disorder, and depression.
Roy H. Perlis, MD
Professor of Psychiatry, Harvard Medical School
Vijaya Ramesh, PhD
Neuroscientist, Massachusetts General Hospital
Professor of Neurology, Harvard Medical School
My lab has been primarily working on understanding the pathophysiology of two different inherited neurocutaneous syndromes, Neurofibromatosis 2 (NF2) and Tuberous Sclerosis Complex (TSC). We have collaborative studies with investigators outside MGH for these studies. We also collaborate with Dr. Xandra Breakefield and Dr. Casey Maguire labs for gene therapy studies of NF2 and TSC.
Vijaya Ramesh, PhD
Professor of Neurology, Harvard Medical School
Jonathan Rosand, MD, MSc
J. P. Kistler Endowed Chair in Neurology, Massachusetts General Hospital
Professor of Neurology, Harvard Medical School
The hallmark of our work is the combination of careful clinical characterization of patients with the most rigorous approaches to genetics. We work in partnership with patients and their families to understand the factors that contribute to maintaining vascular brain health across the lifespan. We are a leading contributor to the performance and analysis of high-throughput genome-wide association and sequencing studies in stroke and related traits. At our core, we serve as a training ground for outstanding scientists and clinician-scientists who go on to become world-class leaders in the field. The lab has created a legacy of multidisciplinary teams that are successfully tackling some of the most pressing challenges in brain disease. Among these teams is the International Stroke Genetics Consortium, which we founded in 2007 to bring together the world’s pre-eminent stroke investigators.
Jonathan Rosand, MD, MSc
Professor of Neurology, Harvard Medical School
Jeremiah M. Scharf, MD, PhD
Physician-Scientist, Massachusetts General Hospital
Assistant Professor of Neurology, Harvard Medical School
The Scharf lab investigates the genetic and neurobiological mechanisms of Tourette Syndrome (TS) and related developmental neuropsychiatric disorders that lie at the interface between traditional concepts of neurologic and psychiatric disease, including obsessive compulsive spectrum disorders (OCD/OCSD) and attention-deficit hyperactivity disorder (ADHD). We conduct genetic and clinical research to identify both genetic and non-genetic risk factors that contribute to the predisposition of TS, ADHD, and OCD in patients and families. We hope to identify novel targets for treatment, to understand the course of TS and related conditions at a patient-specific level, and to better predict treatment response.
Jeremiah M. Scharf, MD, PhD
Assistant Professor of Neurology, Harvard Medical School
Ihn Sik Seong, PhD
Geneticist, Massachusetts General Hospital
Associate Professor of Neurology, Harvard Medical School
Seong laboratory is focused on understanding the fundamental mechanism of neurodegenerative diseases and neurodevelopmental disorders using precise genetic disease cells/mice models. Our research into the structural, biochemical, and functional properties of the full-length huntingtin protein continues to aim to understand Huntington’s disease (HD) at its root cause.
Ihn Sik Seong, PhD
Associate Professor of Neurology, Harvard Medical School
Susan A. Slaugenhaupt, PhD
Professor of Neurology (Genetics), Harvard Medical School
Investigator, Massachusetts General Hospital
My research focuses on two neurological disorders, familial dysautonomia (FD) and mucolipidosis type IV (MLIV), as well as the common cardiac disorder mitral valve prolapse (MVP). Our work is focused on gene discovery and therapeutic development, specifically targeting mRNA splicing.
Susan A. Slaugenhaupt, PhD
Professor of Neurology (Genetics), Harvard Medical School
Jordan W. Smoller, MD, ScD
MGH Trustees Endowed Chair in Psychiatric Neuroscience, Massachusetts General Hospital
MGH Trustees Endowed Chair in Psychiatric Neuroscience, Massachusetts General Hospital
Professor of Psychiatry, Harvard Medical School
The focus of Dr. Smoller’s research interests has been:
- Understanding the genetic and environmental determinants of psychiatric disorders across the lifespan.
- Integrating genomics and neuroscience to unravel how genes affect brain structure and function.
- Using “big data”, including electronic health records and genomics, to advance precision medicine.
Jordan W. Smoller, MD, ScD
Professor of Psychiatry, Harvard Medical School
Alexander Soukas, MD, PhD
Associate Professor of Medicine, Harvard Medical School
Associate Professor of Medicine, Massachusetts General Hospital
Aging is the single, greatest contributor to nearly every disease and condition that affects us after our youth. Diabetes, obesity, heart disease, stroke, cancer, osteoporosis, and dementia are all diseases of aging. In the Soukas Laboratory, we endeavor to figure out how things go wrong in the cells of the body in aging, and more excitingly, how to fix what goes wrong. Our findings have the ability to impact not one, but nearly every disease that impacts humankind. We have the major goal of identifying molecular “switches” that can be thrown to turn back the clock on the aging process, promoting healthy aging and staving off aging-associated diseases.
Alexander Soukas, MD, PhD
Associate Professor of Medicine, Harvard Medical School
David A. Sweetser MD, PhD
Pediatrician, Massachusetts General Hospital
Assistant Professor of Pediatrics, Harvard Medical School
The Sweetser Lab has two areas of focus. One is rare disease work. Our work with the Undiagnosed Diseases Network takes a deep dive into phenotyping, evaluations, and genome sequencing, and functional characterization to identify novel genetic disorders. We also have focused projects in Pitt Hopkins syndrome, IQSEC2, and epileptic encephalopathies with Natural History studies and creating patient derived stem cell models. The second area of research seeks to characterize the leukemic stem cell niche and develop targeted cancer therapies.
David A. Sweetser MD, PhD
Assistant Professor of Pediatrics, Harvard Medical School
Michael E. Talkowski, PhD
Investigator, Massachusetts General Hospital
Professor of Neurology, Harvard Medical School
The Talkowski lab integrates molecular and computational genomics methods to study the genetic etiology of disorders affecting prenatal, neonatal, and early childhood development, as well as neurodevelopmental and psychiatric disorders. Our lab is also interested in variant-to-function studies to understand genomic perturbations to regulatory pathways in rare diseases and the applications of emerging technologies to clinical diagnostic screening.
Michael E. Talkowski, PhD
Director, CGM; Professor of Neurology, Harvard Medical School
Miriam Udler, MD, PhD
Assistant Professor, Harvard Medical School
Attending in Endocrinology, Massachusetts General Hospital
Director, MGH Diabetes Genetics Clinic
We focus on advancing precision diagnosis and management of metabolic diseases.
Miriam Udler, MD, PhD
Attending in Endocrinology, Massachusetts General Hospital
James A. Walker, PhD
Assistant in Genetics, Massachusetts General Hospital
Assistant Professor of Neurology, Harvard Medical School
Our research focuses primarily on neurofibromatosis type 1 (NF1), a genetic disorder with an incidence of one in 3,000–4,000 people. Most adults with NF1 develop neurofibromas – benign, but often disfiguring, tumors associated with peripheral nerves.
James A. Walker, PhD
Assistant Professor of Neurology, Harvard Medical School
Vanessa C. Wheeler, PhD
Research Geneticist, Massachusetts General Hospital
Associate Professor of Neurology, Harvard Medical School
Repeat expansion diseases such as Huntington’s disease (HD) are characterized by the instability of their causative repeat mutations. The inherited repeat undergoes further somatic expansion that drives disease pathogenesis. Our lab uses patients and model systems to characterize and uncover the underlying modifiers and mechanisms of repeat instability in order to identify targets for disease-modifying therapies.
Vanessa C. Wheeler, PhD
Associate Professor of Neurology, Harvard Medical School
Wei Zhou, PhD
Assistant investigator, Massachusetts General Hospital
Our lab focuses on developing and applying statistical methods to uncover genetic risk factors for human diseases using large-scale biobanks as well as leveraging high-dimensional omics data to interpret the genetic association discoveries.
Wei Zhou, PhD
Assistant investigator, Massachusetts General Hospital
We are hiring! We are inviting applications for full-time CGM faculty with an Assistant or Associate Professor of Neurology appointment at Harvard Medical School (HMS), commensurate with accomplishments and experiences. See more and apply on our careers page >
The Center for Genomic Medicine (CGM) comprises one of the largest and most vibrant hubs of genomic medicine research in the world. The CGM includes 46 faculty collaborating to define the ‘genomic medicine cycle’ – which envisages a genomics community seeking to advance research from basic genomics research to ultimately using genome information for diagnostics and targeted therapeutics. All of our investigators are faculty at Harvard Medical School, and many members of our community are also investigators at the Broad Institute of Harvard and MIT.
